Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS has announced that BREXAFEMME (ibrexafungerp tablets) is now accessible to about 55% of commercially insured U.S. patients, covering more than 93 million lives. This first-in-class oral antifungal treatment addresses an unmet need for vaginal yeast infections, particularly in resistant cases. The drug, approved by the FDA in June 2021, demonstrates efficacy against Candida species. The company anticipates ongoing increases in insurance coverage and prescription volumes as they pursue broader access for women.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in three women’s health conferences throughout April 2022, showcasing its commitment to advancing women’s health. The company, known for developing BREXAFEMME (ibrexafungerp), the first oral treatment for vaginal yeast infections approved in over 20 years, aims to discuss innovative treatments. The conferences include the ACOOG Annual Conference (April 3-8), NBNPA Conference (April 29-30), and Ms. Medicine Women’s Health Conference (April 28-30). Each event will address significant advancements in women’s health.
SCYNEXIS reported significant achievements for 2021, with BREXAFEMME generating $1.1 million in net revenues. The fourth quarter alone saw revenues of $0.6 million. The product is now covered by commercial insurance representing 48% of insured lives. The successful CANDLE Phase 3 trial claims statistical superiority over placebo for ibrexafungerp in treating recurrent vulvovaginal candidiasis. SCYNEXIS has projected a cash runway extending into the second quarter of 2023.
SCYNEXIS, Inc. (NASDAQ: SCYX) will announce its fourth quarter and full year 2021 financial results on March 29, 2022. The company, dedicated to developing innovative medicines for difficult-to-treat infections, plans to hold a conference call at 8:30 a.m. EDT to discuss the results. SCYNEXIS's lead product, ibrexafungerp, is a systemic antifungal approved by the FDA on June 1, 2021, and is set for launch in the U.S. as BREXAFEMME. The company is continuing investigations into ibrexafungerp for other significant fungal infections.
Summary not available.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced grants of stock options and Restricted Stock Units (RSUs) to three new employees, totaling 28,000 stock options at an exercise price of $4.18 and 11,500 RSUs. This move aims to attract talent in the biotechnology sector focusing on innovative treatments for drug-resistant fungal infections. The options will vest over a four-year period, while the RSUs will vest over three years. These grants are part of SCYNEXIS’ 2015 Inducement Award Plan, aligned with their mission to develop medicines like ibrexafungerp, aimed at combating serious fungal infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in several medical events throughout March 2022. Key highlights include a live panel discussion on drug development in Women’s Health, led by CEO Marco Taglietti. The company will attend three in-person conferences: ISSWSH from March 3-6 in Dallas, CREOG & APGO Annual Meeting from March 9-12 in Orlando, and AMCP from March 29-April 1 in Chicago. Additionally, SCYNEXIS will participate in a virtual investor panel at Maxim Group’s Annual Growth Conference on March 28.
For more details, visit www.scynexis.com.
SCYNEXIS reported successful results from the Phase 3 CANDLE study for ibrexafungerp, the only oral fungicidal treatment for vaginal yeast infections. The study showed 65.4% of patients treated with ibrexafungerp had clinical success at 24 weeks, surpassing the 53.1% success rate of the placebo group. The company plans to submit a supplemental New Drug Application (sNDA) for BREXAFEMME for preventing recurrent vaginal yeast infections in the first half of 2022, with anticipated FDA approval by year-end. Ibrexafungerp has potential benefits for patients not responding to fluconazole.
SCYNEXIS, Inc. (NASDAQ: SCYX) has granted stock options and Restricted Stock Units (RSUs) to five new employees, totaling 41,000 stock options at an exercise price of $4.90 and 16,000 RSUs. These grants serve as inducements for accepting employment offers. The stock options vest over four years, with a one-year cliff, while RSUs vest over two years. SCYNEXIS is focused on developing innovative antifungal medicines, including its lead product, ibrexafungerp, recently approved by the FDA for treating fungal infections.
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology firm, announced that CEO Marco Taglietti will present at two virtual investor conferences in January 2022. The events are the LifeSci Partners 11th Annual Corporate Access Event on January 7 at 10:00 a.m. ET and the H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference from January 10-13, featuring a corporate update webcast. SCYNEXIS is focused on developing innovative treatments for drug-resistant infections, including its lead asset, ibrexafungerp, approved by the FDA on June 1, 2021.